Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

@article{Scott2012ReducedAntigenCD,
  title={Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine, Adsorbed (Boostrix{\textregistered})},
  author={Lesley J. Scott and Paul L. McCormack},
  journal={BioDrugs},
  year={2012},
  volume={27},
  pages={75-81}
}
Reduced-antigen, combined diphtheria, tetanus, and three-component acellular pertussis vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus, and pertussis. In clinical trials, a single booster dose of Tdap induced high seroprotective levels of antibodies to its three component acellular pertussis antigens in virtually all children and adolescents, and in a high proportion of adults and elderly individuals, at ≈1 month post-vaccination, irrespective of their… 

Evaluation of a new syringe presentation of reduced-antigen content diphtheria, tetanus, and acellular pertussis vaccine in healthy adolescents - A single blind randomized trial

Clinical results complement the technical data and support the use of the new syringe presentation to deliver the dTpa vaccine.

Immune persistence after pertussis vaccination

Data on immune persistence after different pertussis vaccinations is presented and the findings from countries with different vaccination strategies are compared.

Pertussis re-emergence in the post-vaccination era

The simultaneous use of more than one strategy, including cocooning strategy plus vaccination of adolescents and adults, seems to be the most reasonable preventive measure for the control of pertussis.

Predictors of Full Childhood Immunization Status in Owerri, Nigeria

This study investigated the influence of maternal satisfaction with postnatal services and paternal support on full childhood immunization status and examined the association between maternal factors and the maternal retention of immunization documentation in Owerri, Nigeria to help to evolve a system that may increase childhood immunized status and reduce vaccine-preventable diseases in Owarri and serve as a model for other countries.

The promise of reverse vaccinology.

Machine learning methods have been used to improve the ability of RV approaches to identify vaccine candidates and it is envisaged that RV approaches will facilitate rapid vaccine design with less reliance on conventional animal testing and clinical trials in order to curb the threat of antibiotic resistance or newly emerged outbreaks of bacterial origin.

Clinical Experimental Vaccine Research

    References

    SHOWING 1-10 OF 92 REFERENCES

    Reduced-Antigen, Combined Diphtheria, Tetanus and Acellular Pertussis Vaccine, Adsorbed (Boostrix®)

    Tdap is highly immunogenic, with low reactogenicity, in all age groups and appears suitable for targeted and/or repeat Tdap boosters in children, adolescents, adults and elderly individuals as part of immunization strategies that may prove beneficial in further limiting the burden of pertussis.

    Combined, Reduced-Antigen Content Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Boostrix®)

    High seroprotection rates against diphtheria and tetanus were demonstrated with Boostrix® and a five-pertussis component Tdap booster vaccine (Adacel®) in a large, randomized study in adults; Boostrix was noninferior to Adacel®, for these outcomes.

    Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Boostrix™)

    Numerous studies in preschool and older children, as well as in adolescents and adults, have demonstrated that a single dose of dTpa (Boostrix™), administered by deep intramuscular injection, is highly immunogenic for all its component toxoids and antigens, regardless of subjects’ prior vaccination history and pre-vaccination serologic status.

    Reduced-Antigen, Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine, Adsorbed (Boostrix® US Formulation)

    Boostrix® US formulation Tdap had a similar reactogenicity profile, including solicited local reactions and general symptoms, to that of the approved Td vaccine in the pivotal US study, and was similar to the primary safety endpoint, namely the incidence of grade 3 pain at the injection site within the 15-day post-vaccination period.

    Reduced-Antigen Combined Diphtheria-Tetanus-Acellular Pertussis Vaccine (Boostrix™)

    The most frequently reported local adverse reactions following immunisation with dTpa included pain, redness and swelling; general symptoms included fatigue, headache and fever.

    Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents

    In adolescents, the studied Tdap was safe and immunogenic and induced pertussis antibodies that were higher than those associated with efficacy in infants.

    Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.

    A second dTpa booster was highly immunogenic and well tolerated in this population of young adults and supports the use of this vaccine as a decennial booster.
    ...